1/33
Elevated levels of growth-related hormones in autism and autism spectrum disorder / JL Mills; ML Hediger; CA Molloy; GP Chrousos; P Manning Courtney; KF Yu; et.al..-- pp. 230-37.-- En: Clinical Endocrinology (Oxf).-- 67, 2 (2007)
TRASTORNO AUTISTICO   GLANDULAS SUPRARRENALES   CEFALOMETRIA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   NIÑO   PREESCOLAR
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-0725
Tipo de Material:
Separata

    OBJECTIVE: Children with autism are known to have larger head circumferences; whether they are above average in height and weight is less clear. Moreover, little is known about growth-related hormone levels in children with autism. We investigated whether children with autism were taller and heavier, and whether they had higher levels of growth-related hormones than control children did. DESIGN: A case-control study design was employed. PATIENTS: Boys with autism spectrum disorder (ASD) or autism (n = 71) and age-matched control boys (n = 59) were evaluated at Cincinnati Children's Hospital. MEASUREMENTS: Height, weight and head circumference were measured. Blood samples were assayed for IGF-1 and 2, IGFBP-3, growth hormone binding protein (GHBP) and for dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)....Continua.

Ver separata




2/33
Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome / SA Lieberman; GE Butterfield; D Harrison; AR Hoffman.-- pp.404-410.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 78, 2 (1994)
FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   SINDROME DE INMUNODEFICIENCIA ADQUIRIDA   PACIENTES
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-2110
Tipo de Material:
Separata




3/33
Ongoing assessment of nutritional status in children with malignant disease / SP Attard Montalto; J Hadley; JE Kingston; OB Eden; V Saha.-- pp. 393-403.-- En: Pediatric Hematology and Oncology.-- 15, 5 (1998)
NEOPLASIAS   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   INGESTION DE ENERGIA   PROTEINAS   ANTROPOMETRIA   NIÑO   ADOLESCENTE
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-2895
Tipo de Material:
Separata

    The nutritional status of a child on cancer therapy influences both tolerance of and response to treatment. However, it is difficult to assess nutritional status on a daily basis because an accurate quantitation of the calorie intake is difficult. Anthropometric and biochemical parameters are prone to error and often reflect past rather than current nutritional status. In practice, a subjective clinical assessment is usually relied upon. This study objectively appraises the value of such an assessment. Based on clinical symptoms that alter oral intake and absorption of food, a scoring system was designed to assess nutritional status on a day to day basis. A symptom score (SS) of 10 implied [quot ]normality[quot ]; 0 indicated maximum debility....Continua.

Ver separata




4/33
The growth hormone-insulin-like growth factor axis in adult patients with Prader Willi syndrome / C Hoybye; J Frystyk; M Thorén.-- pp. 269-274.-- En: Growth Hormone & IGF Research.-- 96 (2003)
SINDROME DE PRADER WILLI   ADULTO   OBESIDAD   HORMONA DEL CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   TRATAMIENTO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-2985
Tipo de Material:
Separata

    Objective. Prader Willi syndrome (PWS) is a genetic disorder characterised by short stature, extreme obesity, body composition abnormalities and behavioural problems. Hypothalamic dysfunction with low growth hormone (GH) secretion and low levels of GH-related growth factors is common. However, the interpretation is difficult because of the concomitant obesity, which in itself has important effects on the GH-IGF-I-system. We therefore analysed free and total IGF-I, total IGF-II and their binding proteins in obese PWS adults before and during 12 months GH treatment. Seventeen adults, 9 men and 8 women, 17-32 years of age with a mean BMI of 35 +- 2.3 kg/m2 participated. All had clinical PWS. They were randomized to treatment with placebo or GH (Genotropin, Pharmacia) 0.8 IU (0.26 mg) for one month, and then 1.6 IU (0.53 mg) for 5 months. Subsequently GH doses were individually titrated to normal levels for age. Overnight fasting levels of free and total IGF-I, total IGF-II, GH-binding protein (GHBP) and IGF-binding proteins (IGFBP)-1, -2 and -3 were measured by RIA at baseline and after 6 and 12 months GH treatment. Mean levels+-SEM of free IGF-I were 1.02+-0.12 lg/L as compared to a reference value of 0.950.15 lg/L, while mean total IGF-I was 128 +- 15 lg/L (212+-14 lg/L) and total IGF-II was 704+-45 lg/L (825+-34 lg/L). Mean IGFBP-2 158+-24 lg/L (764+-72 lg/L) and GHBP 2.65 nmol/L (1.71+-0.31 nmol/L). IGFBP-1 and IGFBP- 3 levels were normal. Both free and total IGF-I increased significantly during GH treatment, while IGF- and GH-binding proteins as well as total IGF-II remained unchanged.
    Conclusion. Low total IGF-I and, in relation to the obesity, low free IGF-I, low total IGF-II and non-suppressed IGFBP-1 are consistent with the concept that PWS patients have a partial GH deficiency, which can be corrected by GH replacement.

Ver separata




5/33
Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism / R Vanhala; U Turpeinen; R Riikonen.-- pp. 614-16.-- En: Developmental Medicine and Child Neurology.-- 43, 9 (2001)
TRASTORNO AUTISTICO   AUTISMO INFANTIL   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   NIÑO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-2994
Tipo de Material:
Separata

    Autism is a behaviourally defined syndrome characterized by disturbances of social interaction and communication and restrictions of behaviour patterns and imagination. The pathogenesis of autism is unknown but it is suspected that a number of genetic factors may be involved. Neurotrophic factors such as insulin-like growth factor-I (IGF-I) play a role in early brain development. The aim of this study was to determine whether IGF-I levels might be associated with the development of autism. IGF-I levels were measured in the CSF of 11 children with autism (4 females, 7 males; mean age 3.8 years, SD 1.1) using a sensitive radioimmunoassay method and compared with levels in 11 control participants (6 females, 5 males; mean age 3.8 years). Levels of IGF-I in the CSF were statistically significantly lower in the children with autism than in the control children (p=0.03). IGF-I may play a role in pathogenetic mechanisms of autism and the role of neurotrophic factors in autism and other neurodevelopmental diseases should be studied further.




6/33
Correlations between bone mineral density, insulin like growth factor I and auxological variables / MN Moreira Andres; K Papapietro; FJ Cañizo; J Rejas; L Larrodera; FG Hawkins.-- pp.573-579.-- En: European Journal of Endocrinology.-- 132 (1995)
DENSIDAD OSEA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   NIÑO   ANTROPOMETRIA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3271
Tipo de Material:
Separata




7/33
Nutritional status of children with moderate chronic renal failure / G Orejas Rodriguez Arango; F Santos Rodriguez; S Malaga Guerrero; C Rey; A Cobo Ruisanchez; M Simarro.-- pp.52-56.-- En: Pediatric Nephrology.-- 9 (1995)
INSUFICIENCIA RENAL CRONICA   INSULINA   NUTRICION   EVALUACION NUTRICIONAL   UREMIA   NIÑO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3283
Tipo de Material:
Separata




8/33
Nutritional regulation of insulin like growth factor I / JM Ketelslegers; D Maiter; M Maes; LE Underwood; JP Thissen.-- pp.50-57.-- En: Metabolism.-- 44, 10 (1995)
NUTRICION   CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3314
Tipo de Material:
Separata




9/33
Growth hormone secretion in poorly growing children with renal hypophosphataemic rickets / G Saggese; GI Baroncelli; S Bertelloni; G Perri.-- pp.548-555.-- En: European Journal of Pediatrics.-- 153 (1994)
NIÑO   CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3399
Tipo de Material:
Separata




10/33
Growth deficits in children with attention deficit hyperactivity disorder / T Spencer; J Bierderman; T Wilens.-- pp.501-506.-- En: Pediatrics.-- 102 (1998)
FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   TRASTORNO POR DEFICIT DE ATENCION CON HIPERACTIVIDAD   NIÑO   TRASTORNOS DEL CRECIMIENTO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3520
Tipo de Material:
Separata




11/33
Hepatic growth hormone receptor, insulin-like growth factor I, and insulin-like growth factor-binding protein messenger RNA: expression in pediatric liver disease / RIG Holt; PA Crosse; JS Jones; AJ Baker; B Portmann; JP Miell.-- pp.1600-1606.-- En: Hepatology.-- 26 (1997)
FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   NIÑO   COMPOSICION CORPORAL   ATRESIA BILIAR   PEDIATRIA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3572
Tipo de Material:
Separata




12/33
The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa / M Hotta; I Fukuda; K Sato; N Hizuka; T Shibasaki; K Takano.-- p. 200-6.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 85, 1 (2000)
ADOLESCENTE   ADULTO   ANOREXIA NERVIOSA   MARCADORES BIOLOGICOS   INDICE DE MASA CORPORAL   PESO CORPORAL   REABSORCION OSEA   HUESOS   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   PROTEINA 2 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   PROTEINAS DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   ESTADO NUTRICIONAL   OSTEOCALCINA   NUTRICION PARENTERAL TOTAL
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3802
Tipo de Material:
Separata

    Malnutrition is one of the risk factors for bone loss in patients with anorexia nervosa (AN). To clarify the effects of nutritional status on bone metabolism, we examined the relationship between serum levels of nutritional indicators [insulin-like growth factor I (IGF-I), IGF-binding protein-2 (IGFBP-2), and IGFBP-3] and markers for bone metabolism [serum osteocalcin and urinary excretion of C-terminal telopeptide of collagen type I (CrossLaps)] in 45 AN out-patients, including 8 severely malnourished patients who required hospitalization and iv hyperalimentation (IVH). Compared to healthy subjects, serum IGF-I and IGFBP-3 were lower, whereas IGFBP-2 was higher in out-patients who had a body mass index (BMI) less than 16.5 kg/m2. In these patients, urinary excretion of CrossLaps, a marker of bone resorption, was higher, whereas serum osteocalcin, a marker of bone formation, was lower than those in control subjects. All of these parameters were normal in patients whose BMI ranged from 16.5-18.5 kg/m2. Serum levels of osteocalcin correlated positively with BMI (r = 0.512; P<0.0001), IGF-I (r = 0.558; P<0.0001), and IGFBP-3 (r = 0.369; P<0.001) in AN out-patients. In the 8 severely malnourished AN patients, serum levels of IGF-I and osteocalcin significantly increased 3 and 7 days, respectively, after the start of a 5-week IVH therapy regimen and reached normal levels within 5 weeks, accompanied by still elevated urinary excretion of CrossLaps. The present study demonstrates that an improvement in nutritional status in AN patients during IVH therapy rapidly increases the serum IGF-I levels, followed by a progressive increase in osteocalcin, suggesting immediate start of bone formation. However, increased bone resorption appears to continue for at least 5 weeks.




13/33
Growth and growth factors in premature infants receiving dexamethasone for bronchopulmonary dysplasia / AM Skinner; M Battin; A Solimano; J Daaboul; HF Kitson.-- p.539-546.-- En: American Journal of Perinatology.-- 14, 9 (1997)
CONSTITUCION CORPORAL   DISPLASIA BRONCOPULMONAR   ESTUDIO COMPARATIVO   DEXAMETASONA   INGESTION DE ENERGIA   GLUCOCORTICOIDES SINTETICOS   NUTRICION DEL LACTANTE   RECIEN NACIDO   ENFERMEDADES DEL RECIEN NACIDO   PREMATURO   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   MODELOS LINEALES   FACTORES DE TIEMPO   AUMENTO DE PESO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4127
Tipo de Material:
Separata




14/33
Nutritional management and growth hormone treatment of preterm infants born small for gestational age / HN Lafeber.-- p.202-205.-- En: Acta Paediatrica. Supplementum.-- 423 (1997)
ENSAYOS CLINICOS CONTROLADOS   PROTEINAS EN LA DIETA   RETARDO DEL CRECIMIENTO FETAL   GLUCOSA   RECIEN NACIDO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   NECESIDADES NUTRICIONALES   SOMATROPINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4242
Tipo de Material:
Separata




15/33
Nutritional factors and thalassaemia major / GJ Fuchs; P Tienboon; S Linpisarn; S Nimsakul; P Leelapat; S Tovanabutra; V Tubtong; M DeWier; RM Suskind.-- p.224-227.-- En: Archives of Disease in Childhood.-- 74, 3 (1996)
BETATALASEMIA   ANTROPOMETRIA   ESTATURA   PESO CORPORAL   INFANTE   GRASAS EN LA DIETA   TRASTORNOS DEL CRECIMIENTO   LACTANTE   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   TRASTORNOS NUTRICIONALES   ESTADO NUTRICIONAL
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4251
Tipo de Material:
Separata




16/33
Regulation of growth in children with chronic illness. Therapeutic implications for the year 2000 / MS Kappy.-- p.489-493.-- En: American Journal of Diseases of Children.-- 141, 5 (1987)
NIÑO   DIABETES MELLITUS   INSULINO DEPENDIENTE   GLUCOCORTICOIDES   TRASTORNOS DEL CRECIMIENTO   CARDIOPATIAS CONGENITAS   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   INSUFICIENCIA RENAL CRONICA   HEPATOPATIAS   TRASTORNOS NUTRICIONALES   SOMATOTROPINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4621
Tipo de Material:
Separata

Ver separata



17/33
Concurrent micronutrient deficiencies in lactating mothers and their infants in Indonesia / MA Dijkhuizen; FT Wieringa; CE West; M Muherdiyantiningsih.-- p.786-791.-- En: American Journal of Clinical Nutrition.-- 73, 4 (2001)
ADOLESCENCIA   ADULTO   ANEMIA FERROPRIVA   ANTROPOMETRIA   BETA CAROTENO   ESTUDIOS TRANSVERSALES   LACTANTE   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   HIERRO   LACTANCIA   MICRONUTRIENTES   LECHE HUMANA   RAZON DE DIFERENCIA   PREVALENCIA   VITAMINA A   DEFICIENCIA DE VITAMINA A   CINC
Categoría geográfica: INDONESIA  
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4929
Tipo de Material:
Separata

    Deficiencies of vitamin A, iron, and zinc are prevalent worldwide, affecting vulnerable groups such as lactating women and infants. However, the existence of concurrent deficiencies has received little attention. OBJECTIVE: The aim was to investigate the extent to which deficiencies of vitamin A, iron, and zinc coexist and the nutritional relation between lactating mothers and their infants. DESIGN: In a cross-sectional survey in rural West Java, Indonesia, 155 lactating mothers and their healthy infants were assessed anthropometrically and blood, urine, and breast-milk samples were obtained. RESULTS: Marginal vitamin A deficiency was found in 54% of the infants and 18% of the mothers. More than 50% of the mothers and infants were anemic and 17% of the infants and 25% of the mothers were zinc deficient. There was a strong interrelation between the micronutrient status of the mothers and infants and the concentrations of retinol and beta-carotene in breast milk. Vitamin A deficiency in infants led to an increased risk of anemia and zinc deficiency (odds ratios: 2.5 and 2.9, respectively), whereas in mothers the risk of anemia and iron deficiency (odds ratios: 3.8 and 4.8, respectively) increased. In infants, concentrations of insulin-like growth factor I were related to concentrations of plasma retinol and beta-carotene but not to zinc. CONCLUSIONS: Micronutrient deficiencies were prevalent in West Java. The micronutrient status of lactating mothers and that of their infants were closely related; breast milk was a key connecting factor for vitamin A status. Furthermore, concurrent micronutrient deficiencies appeared to be the norm.-

Ver separata




18/33
Vitamin A levels and growth hormone axis / R Raifen; Y Altman; Z Zadik.-- pp.279-281.-- En: Hormone Research.-- 46, 6 (1996)
PROTEINAS PORTADORAS   NIÑO   INFANTE   RITMO CIRCADIANO   ESTUDIOS DE SEGUIMIENTO   PROTEINA DE ENLACE DE FACTOR DE CRECIMIENTO   SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   SOMATROPINA   VITAMINA A
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4958
Tipo de Material:
Separata

    Vitamin A (VA) is required for normal growth and development retinoic acid may be the active metabolite through binding to nuclear receptors. Recently a correlation between nocturnal growth hormone (GH) secretion and VA was was found in short slowly growing children. We determined the 24-hour integrated concentration of GH (IC-GH), GH response to provocative stimuli, IGF-I, IGF-binding protein-3 (IGF-BP3) and GH-binding protein (GH-BP) in 34 prepubertal children (25 m/9 f) 5-10 years of age, height -2.5 to 1.5 SDS and body mass index -1.5 to 1.5 SDS for age and sex. Since folic acid, vitamin B12, IGF-I, cholesterol, triglycerides and VA carrier proteins were normal we assumed that no major nutritional deficiency existed. The correlation matrix of the variates tested were p < 0.05 for VA and IC-GH and p < 0.006 for IGF-BP3. It is suggested that VA might have a direct affect on both ICGH and IGF-BP3.-

Ver separata




19/33
Chronic hypoxemia leads to reduced serum IGF-I levels in cyanotic congenital heart disease / B Dündar; A Akçoral; G Saylam; N Unal; T Mese; S Hüdaoglu; B Büyükgebiz; E Büber; A Büyükgebiz.-- p. 431-436.-- En: Journal of Pediatric Endocrinology and Metabolism (JPEM).-- 13, 4 (2000)
ANTROPOMETRIA   NIÑO   INFANTE   CIANOSIS   PROTEINAS EN LA DIETA   INGESTION DE ENERGIA   FEMENINO   TRASTORNOS DEL CRECIMIENTO   CARDIOPATIAS CONGENITAS   HUMANO   LACTANTE   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   MASCULINO   TRASTORNOS NUTRICIONALES   ESTADO NUTRICIONAL   OXIGENO   ANOXIA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-5052
Tipo de Material:
Separata

    Cyanotic congenital heart disease in children commonly causes more pronounced growth retardation in comparison with acyanotic congenital heart disease. Chronic hypoxemia has been suggested as the cause of poor growth in these patients, but the relationship between serum IGF-I levels and chronic hypoxemia is unclear. Serum IGF-I concentrations, oxygen saturation and nutritional status were evaluated in 29 patients with cyanotic congenital heart disease, and serum IGF-I levels were compared with a group of 20 well-nourished, age-matched control children to assess the relationship between IGF-I levels and chronic hypoxemia. The nutritional status of each patient was determined by using anthropometric parameters and calorie and protein intake ratios. The patients were divided into malnourished and well-nourished groups (21 and 8 patients, respectively) according to their nutritional status. Serum IGF-I concentrations were measured in the two patient groups and the controls. The malnourished group had the lowest IGF-I levels (48.14 +/- 21.8 ng/ml, p<0.05). However, the well-nourished group's IGF-I levels were significantly lower than the control subjects' despite improved nutritional status (85.5 +/- 30.2 and 107 +/- 19.7 ng/ml, respectively, p<0.05). In addition, we found a positive correlation between serum IGF-I levels and oxygen saturation of the patients (r=0.402, p<0.05). These findings indicate that chronic hypoxemia has a direct or indirect effect to reduce serum IGF-I concentrations and this may be a cause of the increased growth failure in patients with cyanotic congenital heart disease.

Ver separata




20/33
Serum insulin like growth factor 1 in congenital heart disease / JS Barton; PC Hindmarsh; MA Preece.-- pp.162-163.-- En: Archives of Disease in Childhood.-- 75, 2 (1996)
MARCADORES BIOLOGICOS   INDICE DE MASA CORPORAL   INGESTION DE ENERGIA   FEMENINO   CRECIMIENTO   CARDIOPATIAS CONGENITAS   HUMANO   LACTANTE   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   MASCULINO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-5097
Tipo de Material:
Separata

Ver separata



21/33
Proteins used in nutritional assessment / Spiekerman AM.-- pp. 353-69.-- En: Clin Lab Med.-- 13, 2 (1993)
Notas de Contenido:
Material no impreso
PROTEINAS SANGUINEAS   HUMANO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   EVALUACION NUTRICIONAL   TRASTORNOS NUTRICIONALES   PREALBUMINA   PROTEINAS DE ENLACE DE RETINOL   ALBUMINA SERICA   TRANSFERRINA
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    The importance of maintaining or restoring the size of the protein pool remains the primary objective of nutrition therapy for the hospitalized patient. Also, newer nutritional markers are needed that identify malnourished patients and effectively monitor nutritional intervention on the patient's nutritional status. To do this, one must assess protein pools in an effective manner. Newer protein markers must have a short biologic half-life and reflect protein deficiency with decreasing serum concentrations. The proteins discussed offer unique opportunities for investigating malnutrition in the hospital and clinic setting. More studies to elucidate the effects that diseases and drugs have on these proteins in particular patient subpopulations are needed. Additional methods also need to be developed to make assays for SMC and interleukin cost effective in hospital or clinic settings. In the next decade, certainly more research will be undertaken on these promising new nutritional markers.

Ver separata




22/33
Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation / V Mirlesse; F Frankenne; E Alsat; M Poncelet; G Hennen; D Evain Brion.-- pp. 439-42.-- En: Pediatric Research.-- 34, 4 (1993)
PESO AL NACER   ESTUDIO COMPARATIVO   RETARDO DEL CRECIMIENTO FETAL   EDAD GESTACIONAL   HORMONA DEL CRECIMIENTO   RECIEN NACIDO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   ESTUDIOS LONGITUDINALES   GLANDULA PITUITARIA   PLACENTA   EMBARAZO   VALORES DE REFERENCIA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6029
Tipo de Material:
Separata

    To assess the possible role of placental growth hormone (GH) in fetoplacental growth, we measured placental and pituitary GH (GHN) in maternal plasma by means of two RIA using two MAb (5B4 recognizing both placental GH and GHN, and K24 recognizing only GHN) during pregnancy. IGF-I also was measured by RIA in the same samples after extraction. A transverse study of 186 samples obtained between 8 wk of amenorrhea (WA) and term confirmed the reported rise in GH immunoreactivity with 5B4 after 24 to 25 WA from 12.3 +/- 2.0 mU/L (mean +/- SEM) to a plateau of 27.5 +/- 3.4 mU/L at 34 to 35 WA together with the decrease in GHN to undetectable levels by 24 to 25 WA. IGF-I levels increased from 164.0 +/- 44.6 micrograms/L at 24 to 25 WA to 331.6 +/- 63.6 micrograms/L at term. A longitudinal study of 31 normal pregnant women confirmed this hormonal pattern and the reported placental GH plateau after 35 WA. A drastic decrease in placental GH was observed with the onset of labor (from 26.9 +/- 2.1 to 2.7 +/- 1.1 mU/L), whereas the decrease in IGF-I was not significant (from 212.9 +/- 26.5 to 162.4 +/- 16.9 micrograms/L).(ABSTRACT TRUNCATED AT 250 WORDS).




23/33
IGF-I, IGF-II, free IGF-I and IGFBP-1, -2 and -3 levels in venous cord blood: relationship to birthweight, length and gestational age in healthy newborns / D Klauwer; WF Blum; S Hanitsch; W Rascher; PD Lee; W Kiess.-- pp. 826-33.-- En: Acta Paediatrica: an International Journal of Paediatrics.-- 86, 8 (1997)
PESO AL NACER   SANGRE FETAL   EDAD GESTACIONAL   RECIEN NACIDO   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   PROTEINA 2 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   PROTEINA DE ENLACE DE FACTOR DE CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6039
Tipo de Material:
Separata

    The insulin-like growth factors (IGF-I and IGF-II) and their binding proteins (IGFBPs) have been implicated in regulating fetal growth and development. The aim of this study was to determine whether fetal IGFs correlate with auxologic data at birth and/or gestational age. Venous cord blood was obtained from 138 healthy newborns immediately after birth and clinical data were recorded using a standardized data sheet. For the determination of IGF-I and IGF-II, IGFBP-blocked radioimmunoassays were used. A coated-tube immunoradiometric assay was applied for the measurement of free IGF-I. IGFBP-1, -2, and -3 were measured using specific radioimmunoassays. IGF-I levels were 61 +/- 21 ng ml(-1), median 61 ng ml(-1), range 19-114 ng ml(-1); IGF-II levels were 466 +/- 80 ng ml(-1), median 457 ng ml(-1), range 311-701 ng ml(-1); free IGF-I levels were 2.4 +/- 1.8 ng ml(-1), median 1.8 ng ml(-1), range 0.4-7.8 ng ml(-1). The concentration of IGFBP-1 was 144 +/- 110 ng ml(-1), median 113 ng ml(-1), range 20-626 ng ml(-1); that of IGFBP-2 was 1165 +/- 455 ng ml(-1), median 1119 ng ml(-1), range 440-3466 ng ml(-1). IGFBP-3 levels were 1272 +/- 280 ng ml(-1), median 1272 ng ml(-1), range 600-1966 ng ml(-1). IGF-I levels correlated significantly with IGFBP-3 levels (r = 0.71), birthweight (r = 0.48) and birth length (r = 0.37). There were significant inverse correlations between IGF-I and both IGFBP-1 (r = -0.45) and IGFBP-2 (r = -0.62). Although free IGF-I levels correlated (r = 0.71) with total IGF-I, only marginally significant correlations were found between free IGF-I and birthweight (r = 0.25)...Continúa.




24/33
Third trimester fetal growth and umbilical venous blood concentrations of IGF-1, IGFBP-1, and growth hormone at term / JAD Spencer; TC Chang; J Jones; SC Robson; MA Preece.-- pp. F87-90.-- En: Archives of Disease in Childhood: Fetal and Neonatal Edition.-- 73, 2 (1995)
DESARROLLO EMBRIONARIO Y FETAL   SANGRE FETAL   RETARDO DEL CRECIMIENTO FETAL   HORMONA DEL CRECIMIENTO   RECIEN NACIDO   RECIEN NACIDO PEQUEÑO PARA LA EDAD GESTACIONAL   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   EMBARAZO   TERCER TRIMESTRE DEL EMBARAZO   ESTUDIOS PROSPECTIVOS   ULTRASONOGRAFIA PRENATAL
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6040
Tipo de Material:
Separata

    Insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-1 (IGFBP-1) and growth hormone (GH) concentrations were measured in umbilical venous blood after delivery of 78 term newborn infants. Three groups of pregnancies were prospectively identified during the third trimester, according to fetal size and subsequent fetal growth, assessed by repeated ultrasound scans. Fetal size was considered either appropriate for gestational age (AGA) or small for gestational age (SGA), according to whether the first ultrasound measurement of abdominal circumference was equal to or above, or below the tenth centile for gestational age, respectively. Subsequent fetal growth was quantified by the change in the standard deviation score of abdominal circumference measurements between the first and last scans before delivery. Fetal growth retardation (FGR) was defined as a (negative) change in SD score of greater than -1.5. Eighteen SGA fetuses with evidence of FGR had significantly lower IGF-1 (median 0.05 (range 0.0-0.24) U/ml) at delivery than 35 SGA fetuses with normal growth (median 0.13 (range 0.0-0.94) U/ml; P < 0.05) and 25 AGA fetuses with normal growth (median 0.31 (range 0.0-0.84) U/ml; P < 0.05). The median concentration in the SGA group with normal growth was also significantly lower than that of the AGA group with normal growth. There were no significant differences in IGFBP-1 or GH concentrations between the three groups. These observations indicate that umbilical blood concentrations at birth of IGF-1, but not IGFBP-1 or GH, relate to both fetal size and fetal growth during the third trimester of pregnancies reaching term.




25/33
Placental growth hormone as a potential regulator of maternal IGF-I during human pregnancy / A Caufriez; F Frankenne; Y Englert; J Golstein; F Cantraine; G Hennen.-- pp. E1014-9.-- En: American Journal of Physiology.-- 258, 6 Pt 1 (1990)
ANTICUERPOS MONOCLONALES   HORMONA DEL CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   LACTOGENO PLACENTARIO   EMBARAZO   PRIMER TRIMESTRE DEL EMBARAZO   TERCER TRIMESTRE DEL EMBARAZO   SEGUNDO TRIMESTRE DEL EMBARAZO   PUERPERIO   VALORES DE REFERENCIA   SOMATOMEDINAS
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6041
Tipo de Material:
Separata

    Ninety-three healthy women were investigated during normal pregnancy, and 177 blood samples were obtained at various gestational stages. In 8 of the women, serial measurements were obtained over a period of 16-34 wk from 8 to 40 wk of gestation. In 13 women, daily blood samples were obtained from day 0 to day 6 after delivery. Insulin-like growth factor I (IGF-I) and human placental lactogen (hPL) were measured by radioimmunoassays. Growth hormone (GH) was estimated by two monoclonal antibody-based radioimmunoassays insensitive to physiological concentrations of hPL: the K24 assay, which recognizes only pituitary hGH, and the 5B4 assay, which reacts with all the known pituitary as well as placental GH variants. Placental GH was distinguished from the main pituitary variant through its specific immunoreactivity pattern. Mean plasma levels of IGF-I were relatively stable until 29-30 wk gestation, then increased progressively to reach a maximum at 35-36 wk...Continúa.




26/33
High-dose growth hormone treatment of short children born small for gestational age / F de Zegher; M Maes; SE Gargosky; C Heinrichs; MV Du Caju; G Thiry.-- pp. 1887-92.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 81, 5 (1996)
ESTATURA   PREESCOLAR   TRASTORNOS DEL CRECIMIENTO   HORMONA DEL CRECIMIENTO   RECIEN NACIDO   RECIEN NACIDO PEQUEÑO PARA LA EDAD GESTACIONAL   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   OSTEOCALCINA   AUMENTO DE PESO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6042
Tipo de Material:
Separata

    The effect of GH administration was evaluated over 2 yr in 50 short, prepubertal, non-GH deficient children born small for gestational age, who had been randomly allocated to a group receiving no treatment or daily sc GH treatment at a dose of 0.2 or 0.3 IU/kg. At the start of the study, mean age was 5.2 yr, bone age was 4.0 yr, height SDS was -3.5, height velocity SDS was -0.8, weight SDS was -2.7, and body mass index SDS was -1.9. Catch-up growth was observed in none of the untreated and all of the treated children. The response to GH treatment included a near doubling of growth velocity and of weight gain and a mean height increment of more than 2 SDS. GH treatment was associated with a distinct acceleration of bone maturation. The differences between the growth responses evoked by the two GH doses were minor. The prepubertal GH-induced catch-up growth was associated with elevated serum concentrations of insulin, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and osteocalcin, whereas insulin-like growth factor-II levels remained unaltered. GH treatment was well tolerated. In conclusion, high-dose GH administration over 2 yr is emerging as a potential therapy to increase the short stature that results from insufficient catch-up growth in young children born small for gestational age. The long-term impact of this approach remains to be delineated.




27/33
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society .-- pp. 3990-3.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 85, 11 (2000)
ADOLESCENTE   NIÑO   DIAGNOSTICO DIFERENCIAL   TRASTORNOS DEL CRECIMIENTO   HORMONA DEL CRECIMIENTO   RECIEN NACIDO   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   TAMIZAJE NEONATAL
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6053
Tipo de Material:
Separata




28/33
Consideraciones sobre crecimiento, somatomedina y nutrición / J Tirapegui; SE Fukushima; G Grimaldi.-- pp. 94-104.-- En: Archivos Latinoamericanos de Nutrición.-- 43, 2 (1993)
Notas de Contenido:
Revista en estanteria
ADOLESCENTE   NIÑO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   ESTADO NUTRICIONAL   RATAS   SOMATOMEDINAS
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    The skeletal growth-promoting action of growth hormone appear to be mediated by circulating somatomedins or insulin-like growth factor(s) (IGF), which act directly to promote the proliferation of growing cartilage. The actions of IGF(s) include also insulin-like activity in extraskeletal tissues and mitogenic activity. Serum concentrations of IGF(s) were found to be dependent on hormonal levels and nutritional status and are reduced by malnutrition or dietary restrictions. The actions of somatomedins may be modulated at the tissue level by somatomedins inhibitor, factor that may act to limit growth in conditions of hormonal and/or nutrition deficiency. Plasma concentration of somatomedins are a good marker of acute directional change in nitrogen balance and dietary energy and protein appears to be particularly important for both generation of somatomedins, and their action on growing cartilage. Measurement of somatomedin concentration shows promise as a means for monitoring the response of malnourished children and rats to nutrition repletion.




29/33
Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens / YK van Pareren; SM de Muinck Keizer Schrama; T Stijnen; TC Sas; M Jansen; BJ Otten; et.al..-- pp. 1119-25.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 88, 3 (2003)
ESTATURA   NIÑO   PREESCOLAR   RELACION DOSIS-RESPUESTA A DROGA   ESTRADIOL   HORMONA DEL CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   SINDROME DE TURNER
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6104
Tipo de Material:
Separata

    Although GH treatment for short stature in Turner syndrome is an accepted treatment in many countries, which GH dosage to use and which age to start puberty induction are issues of debate. This study shows final height (FH) in 60 girls with Turner syndrome treated in a randomized dose-response trial, combining GH treatment with low dose estrogens at a relatively young age. Girls were randomly assigned to group A (4 IU/m(2).d; approximately 0.045 mg/kg/d), group B (first year, 4 IU/m(2).d; thereafter 6 IU/m(2).d), or group C (first year, 4 IU/m(2).d; second year, 6 IU/m(2).d; thereafter, 8 IU/m(2).d). After a minimum of 4 yr of GH treatment, at a mean age of 12.7 +/- 0.7 yr, low dose micronized 17beta-estradiol was given orally. After a mean duration of GH treatment of 8.6 +/- 1.9 yr, FH was reached at a mean age of 15.8 +/- 0.9 yr. FH, expressed in centimeters or SD score, was 157.6 +/- 6.5 or -1.6 +/- 1.0 in group A, 162.9 +/- 6.1 or -0.7 +/- 1.0 in group B, and 163.6 +/- 6.0 or -0.6 +/- 1.0 in group C. The difference in FH in centimeters, corrected for height SD score and age at start of treatment, was significant between groups A and B [regression coefficient, 4.1; 95% confidence interval (CI), 1.4, 6.9; P < 0.01], and groups A and C (coefficient, 5.0; 95% CI, 2.3, 7.7; P < 0.001), but not between groups B and C (coefficient, 0.9; 95% CI, -1.8, 3.6). Fifty of the 60 girls (83%) had reached a normal FH (FH SD score, more than -2). After starting estrogen treatment, the decrease in height velocity (HV) changed significantly to a stable HV, without affecting bone maturation (change in bone age/change in chronological age). The following variables contributed significantly to predicting FH SD score: GH dose, height SD score (ref. normal girls), chronological age at start of treatment, and HV in the first year of GH treatment. GH treatment was well tolerated. In conclusion, GH treatment leads to a normalization of FH in most girls, even when puberty is induced at a normal pubertal age. The optimal GH dosage depends on height and age at the start of treatment and first year HV.




30/33
The thrifty phenotype hypothesis and hearing problems / ML Barrenas; A Bratthall; J Dahlgren.-- pp. 1199-1200.-- En: British Medical Journal.-- 327, 7425 (2003)
Notas de Contenido:
Material no impreso
ADULTO   PERDIDA AUDITIVA   SENSORINEURAL   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   MEDIANA EDAD   FENOTIPO   EMBARAZO   EFECTOS TARDIOS DE LA EXPOSICION PRENATAL
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

Ver separata



31/33
How effective and safe is growth hormone therapy in children born small for gestational age? .-- pp. 263-6.-- En: Journal of Pediatric Endocrinology and Metabolism (JPEM).-- 17, Suppl 2 (2004)
Notas de Contenido:
Revista en estantería
HORMONA DEL CRECIMIENTO   GLUCOSA DE LA SANGRE   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   RECIEN NACIDO PEQUEÑO PARA LA EDAD GESTACIONAL
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata




32/33
Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy / J Ayuk; SE Stewart; PM Stewart; MC Sheppard; European Sandostatin LAR Group.-- pp. 375-81.-- En: Clinical Endocrinology (Oxf).-- 60, 3 (2004)
ACROMEGALIA   AGENTES ANTINEOPLASICOS HORMONALES   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   ADULTO   OCTREOTIDO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6553
Tipo de Material:
Separata

    BACKGROUND AND OBJECTIVES: Somatostatin analogues have been used as an adjunct to surgery and radiotherapy in the treatment of acromegaly for over 15 years, but debate surrounds their use as primary therapy. Newman suggested that octreotide was equally effective as primary or adjuvant therapy, but the effects of previous surgery/radiotherapy may have led to a preselection bias. In an attempt to eliminate this bias, the efficacy of the depot somatostatin analogue Sandostatin LAR as primary and adjuvant therapy has been assessed using GH and IGF-I levels at diagnosis as baseline values. DESIGN: We retrospectively analysed the GH and IGF-I data from a large multicentre study in which patients' biochemical response to treatment with the depot somatostatin analogue Sandostatin LAR as primary and adjuvant therapy was assessed. We used GH and IGF-I levels at diagnosis as baseline values to eliminate any preselection bias. PATIENTS AND RESULTS: In 91 patients (42 male) studied, mean serum GH fell from 36.2 +/- 3.3 micro g/l (SEM) at diagnosis to 2.2 +/- 0.2 micro g/l after 48 weeks of treatment (P < 0.0001). In the primary (n = 34) and adjuvant (n = 57) therapy groups, mean GH fell from 30.7 +/- 5.7 to 2.6 +/- 0.4 micro g/l (P < 0.0001) and from 39.5 +/- 4.1 to 2.0 +/- 0.2 micro g/l (P < 0.0001), respectively. Sixty-two percent of patients in the primary therapy group and 70% in the adjuvant therapy group achieved GH < 2 micro g/l....Continua.

Ver separata




33/33
Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy / NJ Hopwood; RL Hintz; JM Gertner; KM Attie; AJ Johanson; J Baptista; et.ál..-- pp. 215-22.-- En: The Journal of Pediatrics.-- 123, 2 (1993)
Notas de Contenido:
Revista en estanteria
ESTATURA   TRASTORNOS DEL CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   INYECCIONES SUBCUTANEAS   PUBERTAD   ANTROPOMETRIA   PROTOCOLOS CLINICOS
Ubicación: CANIA. CD   
Tipo de Material:
Separata

    Short-term administration of human growth hormone to children with idiopathic short stature can improve mean growth rate and predicted adult height. It is yet unknown whether therapy would alter pubertal development or affect final height. Three-year treatment results in a group of children with idiopathic short stature are reported. For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58). After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.....Continua.





33 Registros recuperados

Presentar con el formato: 

Ver selección       Limpiar selección